Oncology Test Portfolio

OncoGxSelect OncoGxSelect™

OncoGxSelect™ analyzes a patient’s tumor for genetic mutations frequently found in select cancers. This test utilizes Next Generation Sequencing (NGS) technology to detect alterations in 12 known oncogenes and is aligned with well-established molecular testing guidelines. Actionable results help guide therapeutic decisions related to targeted cancer therapy. Additionally, OncoGxSelect™ detect all types of mutations (SNV, gene fusion, Indel, CNV) with a high degree of accuracy.

View OncoGxOne™ Comprehensive Panel

Target Oncogenes

ALK BRAF EGFR ERBB2 KIT KRAS
MAP2K1 MET NRAS PIK3CA RET ROS1

Types of Alterations Detected

SNVs1 OncoGxSelect™

SNVs

Fusions OncoGxSelect™

Fusions

CNVS2 OncoGxSelect™

CNVs

Indels OncoGxSelect™

Indels

Relevant Solid Tumor Types

Gene Variant Type Responsive Resistant
ALK EML4-ALK Fusion Crizotinib, Ceritinib, Alectinib Gefitinib, Erlotinib, Afatinib
KIF5B-ALK
T1151_L1152insT Indel Crizotinib
L1152R SNV
C1156Y
F1174L
L1196M
G1202R
S1206Y
G1269A
BRAF V600E SNV Vemurafenib, Dabrafenib, Dabrafenib+Trametinib
ERBB2 G776_777insVC Indel Trastuzumab
A775_G776insYVMA Trastuzumab, Afatinib
G776L SNV
EGFR E746_A750del Indel Gefitinib, Erlotinib, Afatinib
E746_A750delELREA
Exon19_del
D770_N771insSVD
G719A SNV Gefitinib, Erlotinib
G719C Gefitinib, Erlotinib, Afatinib
G719S Gefitinib, Erlotinib
L861Q
D761Y
T790M
L858R Gefitinib, Erlotinib
KRAS G12A SNV Gefitinib, Erlotinib
G12C
G12D
G12R
G12S
G12V
G13A
G13C
G13D
G13R
G13S
G13V
Q61H
Q61K
Q61L
Q61R
MET Amplification CNV Crizotinib
Exon14_skipping Fusion
RET NCOA4-RET Fusion Cabozantinib
CCDC6-RET
KIF5B-RET
ROS1 CD74-ROS1 Fusion Crizotinib
GOPC-ROS1
SLC34A2-ROS1
EZR-ROS1
SDC4-ROS1
TPM3-ROS1
LRIG3-ROS1
Gene Variant Type Responsive Resistant
BRAF V600E SNV Dabrafenib+Trametinib, Vemurafenib+Cobimetinib
V600K Dabrafenib+Trametinib, Vemurafenib+Cobimetinib, Vemurafenib, Dabrafenib
KIT Amplification CNV Imatinib
W557R SNV Imatinib
V559A
V560D
L576P
K642E
MAP2K1 C121S SNV Trametinib
Gene Variant Type Responsive Resistant
ALK STRN-ALK Fusion Crizotinib, Ceritinib
EML4-ALK
BRAF V600E SNV Vemurafenib, Dabrafenib
EGFR Amplification CNV Vandetanib
MET Amplification CNV Cabozantinib
RET NCOA4-RET Fusion Vandetanib, Cabozantinib
CCDC6-RET
C634W SNV Vandetanib
C634R
C634Y
M918T
Gene Variant Type Responsive Resistant
N/A WT Regorafenib Imatinib
N/A WT Cetuximab, Panitumumab
BRAF V600E SNV Cetuximab, Panitumumab
KRAS G12A SNV Cetuximab, Panitumumab
G12C
G12D
G12R
G12S
G12V
G13A
G13C
G13D
G13R
G13S
G13V
Q61H
Q61K
Q61L
Q61R
K117N
A146P
A146T
A146V
NRAS G12A SNV Cetuximab, Panitumumab
G12C
G12D
G12R
G12S
G12V
G13A
G13C
G13D
G13R
G13S
G13V
Q61H
Q61K
Q61L
Q61R
KIT L576P SNV Imatinib
W557R
V559A
K642E
V560del Indel
Gene Variant Type Responsive Resistant
ERBB2 Amplification CNV Trastuzumab,  Trastuzumab+Chemotherapy
EGFR Overexpression Nimotuzumab
Gene Variant Type Responsive Resistant
ERBB2 Amplification CNV Trastuzumab,  Trastuzumab+Chemotherapy
PIK3CA H1047R SNV Temsirolimus, Everolimus

OncoGxSelect™ Report 

OncoGxOne__Plus_Sample_report_thumb OncoGxSelect™

OncoGxSelect™ Information Sheet 

OncoGxSelect_Info_sheet_thumb-1 OncoGxSelect™